Loading patent…
OwnerOleg Epshtein, Evgeny Goldberg +1inventors
InventorsOleg Epshtein, Evgeny Goldberg, Alexandr Dygay
Estimating the term…
The principle of the present invention is the use of an activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to cytokines implicated in the course of inflammation, including autoimmune inflammation, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably according to the homeopathic technology. It is possible to use a mixture of activated forms of antibodies to various cytokines involved in the course of the inflammatory process. In addition, employed as a medicament for correcting pathologic immune reactions based on antibodies to the tumor necrosis factor alpha (TNF-α) can be an activated form of antibodies to TNF-α obtained by multiple consecutive dilutions and exposure to external factors; activation preferably being performed in accordance with the homeopathic technology, and the forms preferably being applied in a mixture of various, predominantly centesimal, homeopathic dilutions.
A method of correcting pathologic immune reactions by administering antibodies to cytokines characterized by the use of activated form of ultra-low doses of monoclonal, polyclonal, or natural antibodies to cytokines involved in the course of inflammation, including autoimmune inflammation, the activated form being prepared by multiple consecutive dilutions and exposure to external factors, preferably following the homeopathic technology.
A medicament for correction of pathologic immune reactions based on antibodies to tumor necrosis factor alpha (TNF-α) characterized by the presence of an activated form of antibodies to TNF-α obtained by multiple consecutive dilutions and exposure to external factors, preferably following the homeopathic technology.
Dependencies are inferred from the claim text.